trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['mbc', 'bcsm']
a practise-changing study and fantastic news for pts with her2-low mbc. t-dxd vs physician's choice
pfs 9.9 vs 4.1m; os 23.4 vs 16.8m; pneumonitis 12.1% #asco2022 #her2_low #bcsm
Clinical oncologist @ QEH, Hong Kong 
Interested in #BCSM #LCSM  
Tweets are my own.